Mallinckrodt Stock Forecast, Price & News

Mallinckrodt's stock was trading at $3.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MNK shares have decreased by 94.5% and is now trading at $0.1680.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 4 sell ratings and 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Mallinckrodt or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Mallinckrodt a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mallinckrodt wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Mallinckrodt is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Mallinckrodt.

Mallinckrodt plc (NYSE:MNK) released its quarterly earnings data on Tuesday, August, 4th. The company reported $1.89 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The company earned $700.90 million during the quarter, compared to analysts' expectations of $630.19 million. Mallinckrodt had a negative net margin of 89.94% and a positive return on equity of 34.26%. The business's quarterly revenue was down 14.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.53 EPS.
View Mallinckrodt's earnings history.

10 analysts have issued 1 year price objectives for Mallinckrodt's shares. Their forecasts range from $1.50 to $4.00. On average, they anticipate Mallinckrodt's stock price to reach $2.70 in the next twelve months. This suggests a possible upside of 1,507.1% from the stock's current price.
View analysts' price targets for Mallinckrodt.

Some companies that are related to Mallinckrodt include Vascular Biogenics (VBLT), Recro Pharma (REPH), Tenzing Acquisition (TZAC), CohBar (CWBR), Citius Pharmaceuticals (CTXR), Avenue Therapeutics (ATXI), Mereo BioPharma Group (MREO), Trevi Therapeutics (TRVI), Daré Bioscience (DARE), Monopar Therapeutics (MNPR), PLx Pharma (PLXP), Merrimack Pharmaceuticals (MACK), Proteostasis Therapeutics (PTI), ASLAN Pharmaceuticals (ASLN) and Seelos Therapeutics (SEEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), (CELG) and Advanced Micro Devices (AMD).

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

Mallinckrodt's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.26%), Morgan Stanley (4.03%), Creative Planning (2.75%), Charles Schwab Investment Management Inc. (1.85%), LSV Asset Management (1.28%) and JPMorgan Chase & Co. (0.68%). Company insiders that own Mallinckrodt stock include Bryan M Reasons and Mark Trudeau.
View institutional ownership trends for Mallinckrodt.

MNK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., LSV Asset Management, BlackRock Inc., SG Americas Securities LLC, AJO LP, and First Trust Advisors LP.
View insider buying and selling activity for Mallinckrodt.

MNK stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Charles Schwab Investment Management Inc., Creative Planning, CI Investments Inc., GSA Capital Partners LLP, and KBC Group NV. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, and Mark Trudeau.
View insider buying and selling activity for Mallinckrodt.

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MNK stock can currently be purchased for approximately $0.17.

Mallinckrodt has a market capitalization of $14.21 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis. Mallinckrodt employs 3,400 workers across the globe.

The official website for Mallinckrodt is www.mallinckrodt.com.

Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected]